We bring a wealth of experience collaborating with biotechnology and pharmaceutical companies throughout the entire development cycle, from early-stage indication prioritization to pre-launch product development and post-launch product optimization. For biotech, we often act as extensions of business development and/or marketing teams.

We have collaborated with leading generics and 505(b)(2) organizations to tackle critical commercial challenges, such as portfolio prioritization, concept identification, TPP value proposition development, and comprehensive value assessments.

We have extensive experience working with a wide range of medical devices. We excel in conducting thorough opportunity assessments and due diligence, providing guidance on commercialization and reimbursement strategies, and establishing the strategic direction for a technology or business unit.

We support private equity firms through the entire investment process, from validating market hypotheses and identifying targets to conducting buy-side diligence, adjusting corporate strategy, and creating sell-side materials.

We have worked with organizations across the entire spectrum of pharma services (CDMOs, CROs, SMOs, and central lab providers) to develop corporate and brand strategies, understand the voice of the customer (value proposition and concept testing), and formulate go-to-market strategies.